In plain language
Survodutide is an experimental medicine that activates two receptors (GLP-1 and glucagon) and is being studied for weight management and for liver disease (MASH). Human trials have reported weight loss and improvements in liver measures, but it is still in development and not approved. Long-term safety is not yet established.
What it is explored for
Survodutide is notable for pairing GLP-1 and glucagon activity, which has drawn interest not only for weight management but also for liver health in MASH. Mid-stage human trials have reported encouraging weight loss and improvements in liver measures. It remains investigational, so its long-term effects are not yet established. Here is where interest is highest.
- Weight management and appetite support
- Liver health and MASH research
- Blood-sugar and metabolic support
- Increased energy expenditure
- Obesity and metabolic-liver research
These are areas of active interest and reported use, not proven outcomes. This peptide carries a moderate (human) rating, see the evidence summary below for how strong the science actually is.
How it works
Survodutide is a peptide that activates both the GLP-1 and glucagon receptors, pairing appetite and glucose effects with increased energy expenditure.
- GLP-1 receptor agonism. Enhances glucose-dependent insulin secretion and reduces appetite.
- Glucagon receptor agonism. Adds glucagon activity that may increase energy expenditure and affect liver fat metabolism, of interest for MASH.
The mechanism is supported by early and mid-stage human data, but survodutide remains investigational and its long-term effects are not established.
Evidence summary
Survodutide has moderate human evidence. Phase 2 trials reported meaningful weight loss and improvements in metabolic dysfunction-associated steatohepatitis (MASH) measures, and further trials are ongoing. As it is not yet approved, the evidence is moderate.
Reported safety & side effects
Reported side effects in trials have been mainly gastrointestinal (nausea, vomiting, diarrhea), consistent with the drug class. As an investigational agent, its full safety profile is not yet established.
Stacking notes
Full stacking guideDo not stack two incretin agonists (for example semaglutide with tirzepatide, or with liraglutide). They act on the same pathway, so side effects like nausea, vomiting, and dehydration add up while there is no evidence of extra benefit. Switch between them under medical care rather than combining.
SemaglutideTirzepatideGeneral educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is survodutide approved?
No. Survodutide is investigational and in clinical trials. It is not FDA-approved.
What is it being studied for?
It is being studied for weight management and for metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease.
How strong is the evidence?
Mid-stage human trials are encouraging for weight loss and liver outcomes, but the data are still maturing and long-term results are unknown, so the evidence is moderate.